Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 2Radiotherapy 2Capecitabine 2tucatinib 1sapanisertib 1pertuzumab 1patritumab deruxtecan 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1fludarabine 1eribulin 1avelumab 1WP 744 1Temozolomide 1Spinal Puncture 1Rituximab 1Psychiatric Rehabilitation 1Phlebotomy 1Methotrexate 1Cyclophosphamide 1Amplified Fragment Length Polymorphism Analysis 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × AZD1390 × CNS × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡